Audience

Read by all 50 of the biggest Pharma companies, like Pfizer and Novartis, as well as thousands of innovative, clinical-stage biotechs.

OUR PLATFORMS draw

252k+
daily email subscribers
700K+
unique monthly visitors
1.8M
average monthly page views
70K+
event registrations

OUR SUBSCRIBERS count

OUR SUBSCRIBERS span

OUR TOP STORIES include

Updated: FDA claims trial 'manipulation' tainted approval of ChemoCentryx drug now owned by Amgen
April 28, 2026
Novo's double departures: As GLP-1 luminary retires, an obesity leader goes to Boehringer Ingelheim
April 10, 2026
Revolution Medicines' pancreatic cancer drug doubles survival time in Phase 3
April 13, 2026
Sanofi’s new CEO faces a reckoning on immunology-focused R&D strategy
April 22, 2026
Updated: FDA will reclassify at least a dozen peptides, teeing up potential telehealth win
April 15, 2026

Get started

Connect with us to request a media kit and learn more about rates and availability.

Julie O'Meara
Julie O'Meara
Executive Director, Brand Partnerships, Endpoints News
Melissa Nazzaro